Najat Khan Sells 23,588 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Najat Khan sold 23,588 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $3.58, for a total value of $84,445.04. Following the transaction, the chief executive officer owned 2,175,796 shares in the company, valued at approximately $7,789,349.68. The trade was a 1.07% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Najat Khan also recently made the following trade(s):

• On Monday, March 9th, Najat Khan sold 28,298 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.35, for a total value of $94,798.30.

Recursion Pharmaceuticals Stock Performance

Shares of Recursion Pharmaceuticals stock opened at $3.32 on Friday. Recursion Pharmaceuticals, Inc. has a one year low of $2.77 and a one year high of $7.18. The company has a market cap of $1.76 billion, a price-to-earnings ratio of -2.77 and a beta of 1.04. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.47 and a current ratio of 5.47. The business’s 50 day moving average price is $3.30 and its 200 day moving average price is $3.82.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The firm had revenue of $6.47 million for the quarter, compared to the consensus estimate of $15.78 million. During the same quarter last year, the business posted ($0.50) earnings per share. The firm’s revenue was down 56.8% compared to the same quarter last year. On average, research analysts predict that Recursion Pharmaceuticals, Inc. will post -0.99 EPS for the current year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Institutional investors have recently modified their holdings of the company. ARK Investment Management LLC grew its stake in shares of Recursion Pharmaceuticals by 1.7% in the third quarter. ARK Investment Management LLC now owns 33,545,499 shares of the company’s stock valued at $163,702,000 after buying an additional 556,868 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Recursion Pharmaceuticals by 10.3% in the third quarter. Vanguard Group Inc. now owns 39,780,153 shares of the company’s stock valued at $194,127,000 after buying an additional 3,708,975 shares in the last quarter. Rafferty Asset Management LLC grew its stake in shares of Recursion Pharmaceuticals by 110.6% in the third quarter. Rafferty Asset Management LLC now owns 750,191 shares of the company’s stock valued at $3,661,000 after buying an additional 394,022 shares in the last quarter. DNB Asset Management AS acquired a new stake in shares of Recursion Pharmaceuticals in the third quarter valued at $1,531,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd grew its stake in shares of Recursion Pharmaceuticals by 94.8% in the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 1,774,995 shares of the company’s stock valued at $8,662,000 after buying an additional 863,910 shares in the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

More Recursion Pharmaceuticals News

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: Recursion’s recent business updates highlighted positive early clinical data and further progress in its AI drug-discovery pipeline, reinforcing investor optimism about the company’s long-term platform potential. Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After AI Pipeline Progress And Stronger-Than-Expected Q1 Results
• Positive Sentiment: The company reported a smaller-than-expected quarterly EPS loss and better-than-expected revenue in its latest earnings release, which helped support the recent rebound in the stock. Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?
• Neutral Sentiment: Recent commentary also focused on Recursion’s valuation and the market’s patience with its AI-biotech story, suggesting investors are weighing pipeline upside against a still-uncertain commercialization timeline. Recursion’s AI Drug Pipeline Progress Tests Investor Patience And Valuation
• Negative Sentiment: CEO Najat Khan sold shares in a pre-arranged trading plan, and Director Namandje Bumpus also sold shares, adding a mild overhang as investors may view insider selling cautiously even though the transactions were planned in advance. SEC filing for CEO Najat Khan sale SEC filing for Director Namandje Bumpus sale

Analysts Set New Price Targets

A number of research firms have commented on RXRX. JPMorgan Chase & Co. reduced their target price on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Needham & Company LLC restated a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Bank of America reduced their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. Finally, Morgan Stanley lifted their target price on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Recursion Pharmaceuticals has a consensus rating of “Hold” and an average price target of $8.10.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.